**To the Editor:** *Mycobacterium kyorinense* is a nonpigmented, slowly growing mycobacterium that was initially isolated in 2007 from a patient with pneumonia in Japan ([@R1]*,*[@R2]). The sequences of the 16S rRNA, *hsp65*, and *rpoB* genes of *M. kyorinense* were closely related to, but different from, those of the type strains of *M. celatum* and *M. branderi*, the 2 most phylogenetically related species ([@R1]). Biochemical tests, such as those for arylsulfatase activity, tellurite reduction, and heat-stable catalase, also distinguish *M. kyorinense* from *M. celatum* and *M. branderi*. In our initial report, in which this species was first recognized, we described 3 strains isolated from Japanese patients ([@R1]). Recently, 1 additional case was reported in Brazil ([@R3]). Here we describe 7 newly identified patients whose infection may have been caused by *M. kyorinense*.

In reviewing the characteristics of these 11 patients (10 from Japan and 1 from Brazil), we found no apparent contacts among them. Nine of the 11 patients had respiratory infections, 1 had lymphadenitis, and 1 had arthritis ([Table](#T1){ref-type="table"}). Of these, 9 patients fulfilled the criteria for infections of clinical significance ([@R4]) and were considered to harbor infection by *M. kyorinense*. Of the 9 patients with respiratory infections, 4 died as a result of the infection. These data suggest that *M. kyorinense* belongs to a class of nontuberculous mycobacteria that are pathogenic for humans and have substantial clinical effects.

###### Clinical characteristics of patients infected with *Mycobacterium kyorinense* and antimicrobial susceptibility of the organism\*

  Characteristic                             Patient/strain no.                                                                                                                                                                  
  ------------------------------------------ -------------------- --------------- --------------- --------------- -------------------- ------------------------------ --------------- --------------- --------------- ---------- --------
  Sex                                        M                    F               M               M               M                    M                              M               F               M               M          M
  Major infection site                       Lung                 Lung            Lung            Lung            Lymph node           Lung                           Lung            Joint           Lung            Lung       Lung
  Specimen                                   Sputum               Sputum          Sputum          BAL             Pus                  BAL                            Sputum          Pus             Sputum          Sputum     Sputum
  Coexisting disease                         COPD                 Breast cancer   None            None            MDS                  None                           None            RA, SLE         None            COPD       NA
  Country                                    Japan                Japan           Japan           Japan           Japan                Japan                          Japan           Japan           Japan           Japan      Brazil
  AM drug MIC, μg/mL                                                                                                                                                                                                             
  STR                                        0.25                 0.25            0.25            S               ND                   0.25                           0.125           0.5             0.25            0.5        S
  EMB                                        4                    4               2               R               128                  2                              1               2               4               4          S
  KAN                                        0.5                  1               0.25            S               ND                   0.5                            0.5             0.5             0.5             0.5        ND
  INH                                        16                   16              32              R               2                    0.5                            8               4               1               4          R
  RIF                                        32                   32              32              R               32                   32                             32              32              32              32         R
  LVX                                        0.125                0.125           0.03            R               0.25                 0.06                           0.06            0.125           0.125           0.25       ND
  CLR                                        0.03                 0.03            0.03            ND              0.03                 0.03                           ND              ND              0.03            0.125      ND
  AMK                                        0.5                  0.5             0.5             ND              0.5                  1                              ND              0.5             0.5             0.5        S
  Clinical efficacy of AM drug combination                                                                                                                                                                                       
  Efficacious                                None                 None            None            None            CLR, RIF, LVX, AMK   CLR, STR, MXF                  None            LVX, EMB, CLR   RIF, CLR, LVX   CLR, LVX   NA
  Nonefficacious                             BIP                  None            RFB, EMB, CLR   INH, EMB, RIF   None                 RIF, EMB, CLR, RIF, AZM, LVX   CLR, RIF, EMB   INH, RIF, EMB   INH, RIF, EMB   RFB, EMB   NA
  Outcome                                    Dead                 Dead            Dead            Dead            Alive                Alive                          Alive           Alive           Alive           Alive      Dead

\*BAL, bronchoalveolar lavage; COPD, chronic obstructive pulmonary disease; MDS, myelodysplastic syndrome; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; NA, not available; AM, antimicrobial; STR, streptomycin; S, sensitive; ND, not done; EMB, ethambutol; R, resistant; KAN, kanamycin; INH, isoniazid; RIF, rifampin; LVX, levofloxacin; CLR, clarithromycin; AMK, amikacin; AM, antimicrobial; RFB, rifabutin; MXF, moxifloxacin; BIP, biapenem; AZM, azithromycin.  †Reported in (*1,2*).  ‡Reported in (*1*). §Reported in (*3*). ¶Strains 1--10 (except for 4): assayed by broth microdilution MIC for nontuberculosis mycobacteria (BrothMIC NTM; Kyokuto Pharmaceutical Industrial Co., Ltd., Tokyo, Japan). Strains 4 and 11: susceptibility test performed by using Vite Spectrum SR (Kyokuto Pharmaceutical Industrial Co., Ltd.) and BACTEC MGIT 960 Mycobacterial Detection System (Becton, Dickinson and Company, Franklin Lakes, NJ, USA), respectively; therefore, numeric MIC data were not available for these strains.

Among the 10 patients for whom precise clinical records were available, 7 patients were treated with first-line tuberculosis drugs, mainly rifampin, isoniazid, and ethambutol, but these therapies were ineffective for all patients. Six patients received a combination of antimicrobial drugs, including macrolides and fluoroquinolones, as first- or second-line chemotherapy, and infection was subdued without recurrence in 5 patients. In contrast, 4 patients with pneumonia who did not receive sufficient therapy with the latter regimen eventually died of infection (3 patients) or breast cancer (1 patient).

MICs of various antimicrobial drugs for the 9 strains of *M. kyorinense* were determined by the broth microdilution method as described ([@R1]). For most strains, the MICs of rifampin, ethambutol, and isoniazid were relatively high, and MICs of macrolides, aminoglycosides, and quinolones were relatively low. Notably, MICs of rifampin were remarkably high (\>32 μg/mL) for all tested strains ([Table](#T1){ref-type="table"}).

Direct sequencing of the 16S rRNA gene, performed as previously described, revealed that 8 of the 9 available *M. kyorinense* isolates were identical across the entire sequenced interval (1,470 bp). The sole exception was the strain from Brazil, which showed a 4-bp substitution that the other strains did not ([@R3]). Although the other 8 strains had identical 16S rRNA sequences, all showed heterogeneity at 9 positions that had not been observed to be heterogeneous in the previous investigation ([@R1]). This observation might reflect the presence of 2 copies of the 16S rRNA gene, as has been occasionally reported for other mycobacterial species, including *M. celatum* ([@R5]). Direct sequencing of the entire *rpoB* gene demonstrated that all strains had identical sequences for this locus. The strains differed from the sequence of *M. tuberculosis* at 15 nt within codons 511--533. At the amino acid level, these changes were synonymous for the 2 species, with the exception of amino acid residue 531. This residue, Ser531 in the *M. tuberculosis* RpoB protein, was replaced by an Asp in *M. kyorinense*. Notably, Ser531 is the most frequent location of substitutions in rifampin-resistant strains of *M. tuberculosis* ([@R6]).

Why *M. kyorinense* has been isolated almost exclusively in Japan is not clear. This tendency may be largely caused by a reporting bias in Japan. However, *M. kyorinense* may have a particular geographic distribution. In this context, it is noteworthy that the sole strain from Brazil characterized in the current study differed slightly in 16S rRNA sequences from the strains isolated in Japan.

It also is notable that the *M. kyorinense* strains isolated so far were invariably resistant to rifampin by in vitro susceptibility testing. Rifampin appeared to have been clinically ineffective in most patients, although definite efficacy of antimicrobial drugs cannot be evaluated by this retrospective type of study. Analysis of the *rpoB* gene sequence of *M. kyorinense* revealed the replacement of aa 531 when compared to the *rpoB* gene sequence of the *M. tuberculosis* protein. This finding suggests that *M. kyorinense* is inherently resistant to rifampin because of the structural features of its RpoB protein. Amino acid replacement at RpoB residue 531 also has been reported in other bacterial species resistant to rifampin, such as *M. celatum*, *Borrelia burgdorferi,* and *Spiroplasma citri* ([@R7]--[@R9]). In any case, understanding the intrinsic resistance of *M. kyorinense* to rifampin is critical for appropriately treating infection by this microorganism. On the basis of the results of our study, we recommend that a combination of fluoroquinolones and macrolides and/or aminoglycosides be used for the initial treatment of infection by *M. kyorinense* in most patients.
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The 16S rRNA and *rpoB* sequences of the *M. kyorinense* type strain KUM 060204 were deposited in GenBank with accession numbers AB370111 and JQ744020, respectively. The variant 16S rRNA sequences of *M. kyorinense* strains isolated from case-patients nos. 9 (KUM060200) and 11 (HF1629) were deposited as JN634643 and JQ717033, respectively.
